Abstract |
Risk of subsequent primary malignancies (SPMs) associated with lenalidomide therapy in multiple myeloma (MM) patients, outside the context of melphalan-based therapy is not established. We assessed the risk of SPMs in lenalidomide treated MM patients (n = 1653) at Moffitt Cancer Center (2004-2012) outside the context of melphalan-based induction therapy and post- melphalan maintenance therapy, via (1) cohort analysis and (2) nested case-control study. Incident SPMs (n = 51) were matched to controls (n = 102) on age at MM diagnosis, gender, follow-up time, and date of diagnosis. Incidence of SPM differed significantly (p = 0.0038) between MM patients treated with and without lenalidomide (5-year incidence estimates of 3.2 and 6.2%, respectively), although not significant after adjustment for age and year of diagnosis (HR = 0.82, 95%CI = 0.43-1.57). Lenalidomide treatment was inversely associated with SPM in the nested case-control analysis (OR = 0.03, 95%CI = 0.002-0.34). In this large cohort of MM patients, lenalidomide treatment was not associated with an increased risk of SPM.
|
Authors | Dana E Rollison, Rami Komrokji, Ji-Hyun Lee, Shalaka Hampras, William Fulp, Kate Fisher, Rachid Baz, Taiga Nishihori, Qiang Xu, Marta Olesnyckyj, Laurie Kenvin, Robert Knight, Daniel Sullivan, Melissa Alsina, William Dalton, Kenneth H Shain |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 58
Issue 3
Pg. 560-568
(03 2017)
ISSN: 1029-2403 [Electronic] United States |
PMID | 27424609
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Case-Control Studies
- Female
- Humans
- Lenalidomide
- Maintenance Chemotherapy
(adverse effects)
- Male
- Middle Aged
- Multiple Myeloma
(drug therapy)
- Neoplasms, Second Primary
(diagnosis, epidemiology, etiology, mortality)
- Odds Ratio
- Population Surveillance
- Retrospective Studies
- Risk Factors
- Thalidomide
(administration & dosage, analogs & derivatives)
|